Literature DB >> 31443922

High nuclear NADPH oxidase 4 expression levels are correlated with cancer development and poor prognosis in hepatocellular carcinoma.

Hyuk Soo Eun1, Kwangsik Chun2, In-Sang Song2, Cheong-Hae Oh1, In-Ock Seong3, Min-Kyung Yeo3, Kyung-Hee Kim4.   

Abstract

NADPH oxidase (NOX) is a key source of reactive oxygen species (ROS). This study aimed to verify NOX2 and NOX4 expression levels in hepatocellular carcinoma (HCC). A total of 134 matched pairs of HCC cells and non-tumour hepatocytes from 134 patients were examined by immunohistochemical staining, and the association of NOX2 and NOX4 expression with clinicopathological parameters was analysed. Western blotting in four HCC cell lines and reverse transcription digital droplet polymerase chain reaction (RT-ddPCR) in 20 pairs of HCC and non-tumour tissue samples were also performed to detect NOX4. Cytoplasmic NOX2 and nuclear NOX4 expression levels were shown by immunohistochemistry to be higher in HCC cells than in non-tumour hepatocytes (p<0.001 each). The western blotting results for NOX4 in four HCC cell lines were consistent with the immunohistochemical results. Increased cytoplasmic expression of NOX2 and NOX4 in HCC cells was significantly correlated with liver cirrhosis (p<0.001 and p<0.031, respectively). However, decreased cytoplasmic expression of NOX2 and NOX4 was significantly correlated with advanced pathological TNM stage (p<0.029 and p<0.007, respectively). Multivariate analysis with clinicopathological parameters showed that high nuclear and low cytoplasmic NOX4 expression levels are correlated with short overall survival (p=0 .021). Our findings imply that cytoplasmic NOX2 and nuclear NOX4 expression is upregulated during HCC development. In particular, NOX4 translocation into the nucleus may affect the development and progression of HCC. NOX2 and NOX4 could be diagnostic markers and have therapeutic implications in HCC.
Copyright © 2019 Royal College of Pathologists of Australasia. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  NADPH oxidase 2; NADPH oxidase 4; diagnosis; hepatocellular carcinoma; prognosis

Mesh:

Substances:

Year:  2019        PMID: 31443922     DOI: 10.1016/j.pathol.2019.05.004

Source DB:  PubMed          Journal:  Pathology        ISSN: 0031-3025            Impact factor:   5.306


  4 in total

1.  Nuclear NADPH oxidase-4 associated with disease progression in renal cell carcinoma.

Authors:  Dharam Kaushik; Keith A Ashcraft; Hanzhang Wang; Karthigayan Shanmugasundaram; Pankil K Shah; Gabriela Gonzalez; Alia Nazarullah; Cooper B Tye; Michael A Liss; Deepak K Pruthi; Ahmed M Mansour; Wasim Chowdhury; Dean Bacich; Hao Zhang; Amanda L Watson; Karen Block; Denise O'Keefe; Ronald Rodriguez
Journal:  Transl Res       Date:  2020-05-31       Impact factor: 7.012

Review 2.  NADPH Oxidases Connecting Fatty Liver Disease, Insulin Resistance and Type 2 Diabetes: Current Knowledge and Therapeutic Outlook.

Authors:  Alberto Nascè; Karim Gariani; François R Jornayvaz; Ildiko Szanto
Journal:  Antioxidants (Basel)       Date:  2022-06-09

3.  Prognostic Value of NOX4 Expression in Cancer Patients: A Systematic Review and Meta-analysis.

Authors:  Hyun Min Koh; Bo Gun Jang; Chang Lim Hyun; Dong Chul Kim
Journal:  Dis Markers       Date:  2022-02-28       Impact factor: 3.434

Review 4.  NADPH Oxidase 4 (NOX4) in Cancer: Linking Redox Signals to Oncogenic Metabolic Adaptation.

Authors:  Ildiko Szanto
Journal:  Int J Mol Sci       Date:  2022-02-28       Impact factor: 5.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.